☰

Parkash S. Gill

Affiliations: 
University of Southern California, Los Angeles, CA, United States 
Area:
Oncology, Molecular Biology
Google:
"Parkash Gill"
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
Ram K. Subramanyan grad student 2006 USC
Jeffrey S. Scehnet grad student 2010 USC
Xiuqing Li grad student 2011 USC

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

De Zoysa P, Liu J, Toubat O, et al. (2020) Delta-like ligand-4 mediated Notch signaling controls proliferation of second heart field progenitor cells by regulating Fgf8 expression. Development (Cambridge, England)
Li GX, Zhang S, Liu R, et al. (2020) Tetraspanin18 regulates angiogenesis through VEGFR2 and Notch pathways. Biology Open
Hanna DL, Iqbal S, Habib D, et al. (2020) A phase Ib study of sEphB4-HSA combined with first-line chemotherapy in patients (pts) with advanced pancreatic (PC) and biliary cancers (BC). Journal of Clinical Oncology. 38: 4640-4640
Sagar V, Vatapalli R, Lysy B, et al. (2019) EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death & Disease. 10: 801
Sadeghi S, Li G, Siddiqi I, et al. (2019) EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC). Journal of Clinical Oncology. 37: 275-275
Li GX, Ma B, Krasnoperov VG, et al. (2019) Abstract 3139: EphB4-EphrinB2 receptor-ligand are downstream effectors and novel targets of PTEN deficient prostate cancer Cancer Research
Thomas JS, Lenz H, Iqbal S, et al. (2018) A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA). Journal of Clinical Oncology. 36: 285-285
McDaniel NK, Cummings CT, Brand TM, et al. (2018) Abstract A140: MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents Molecular Cancer Therapeutics. 17
Merchant AA, Jorapur A, McManus A, et al. (2017) EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 1: 1635-1644
Randolph ME, Cleary MM, Bajwa Z, et al. (2017) EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. Plos One. 12: e0183161
See more...